Pfizer $PFE announced the acquisition of biotech firm Seagen

· Dec 12

Pfizer $PFE announced the acquisition of biotech firm Seagen. This acquisition is another step in Pfizer's efforts to confirm its position as a long-term leader in oncology.

Seagen will bring to Pfizer's portfolio an excellent ADC technology that can deliver a cancer-killing drug directly to cancer cells while sparing other healthy tissues to the maximum extent possible. In the future, we will be able to bring cancer drugs from the antibody conjugate class to patients, which will be a breakthrough technology for the treatment of many types of cancer.

A community member's personal view, not investment advice. Community Guidelines

Bill Combs @billcombs Dec 13

So we'll see how it turns out, as Marek writes, not every acquisition has to be so profitable. However, I have PFE shares in my portfolio and I am waiting for the growth.

Daniela Duong @danieladuong Dec 13

I understand, and I wonder if you will support the rust

Rickie Reeve @rickiereeve Dec 12

I can't really form an opinion on the acquisition. Although it fits their portfolio, I don't know if it was a good deal at that price. I fear that like many of their acquisitions, it will be a long run. But I guess why not.

Daniela Duong @danieladuong Dec 13

It seems like a lot to me too,but I guess they're betting that they want to have as many colonoscopies as possible so they can set their prices 🤔

Wall Street edges higher as oil and yields retreat